It is expected to start this month Mexico end-of-life clinical trials for a candidate COVID-19 vaccine developed by China using technology similar to that of the Pfizer / BioNTech and Moderna vaccines.
The third phase clinical trial for the Chinese Walvax Biotechnology vaccine using messenger RNA (mRNA) technology will start on May 30 with the participation of 6,000 volunteers, clarifies Foreign Minister Marcelo Ebrard in a message on Twitter.
Walvax is working with the Academy of Military Science (AMS) and Suzhou Abogen Biosciences to jointly develop what is known as the ARCoV or ARCoVax vaccine, China’s first mRNA vaccine to enter Phase III clinical trials. ΑΜΠΕ.
The vaccine can be stored at 2-8 degrees Celsius for six months, a less demanding temperature than what Western rivals need, said an AMS researcher who led the plan to develop the vaccine in April. during a presentation at a vaccine event.
Mexico has already received doses of other vaccines against it coronavirus from Chinese Sinovac Biotech and CanSino Biologics and plans to order Sinopharm vaccine doses.
China currently uses five vaccines developed in the country for its population vaccination campaign. However, none of them use mRNA technology.